CVS Books $193 Million Omnicare Guarantee, Then Announces Plan To Split Into Two Companies
CVS backstops the government's Omnicare recovery as it targets a separation into two public companies in the first half of 2028.
CVS Health recorded a $193 million contingent guarantee liability in the third quarter tied to its bankrupt Omnicare unit, according to its 10-Q filed Wednesday. The same filing carries the company's November 4 announcement that it intends to separate into two independent, publicly traded companies.
How the Omnicare guarantee works
The company booked the liability because it now considers a sale of Omnicare's assets likely to happen in the fourth quarter of 2026. Omnicare filed for Chapter 11 in September 2025 and was deconsolidated that month.
Under agreements CVS signed in July 2026 with the Justice Department and the unsecured creditors' committee, and which the bankruptcy court approved in August, the government will receive at least $440 million from Omnicare and CVS combined. CVS will pay $130 million within two weeks of the agreements taking effect, and its appeal and Omnicare's will then be dismissed.
If the Justice Department has not received at least $310 million from Omnicare by March 15, 2028, CVS guarantees collection of the shortfall by March 31, 2028. The effectiveness of the agreements depends on the Omnicare asset sale closing.
The prior quarter's 10-Q carried no such guarantee liability. The charge sits in Corporate/Other and is excluded from adjusted operating income.
The case behind it
A jury found Omnicare and CVS liable in April 2025 in a False Claims Act case over prescriptions filled without valid prescriptions. In July 2025 the court awarded $542 million in penalties against Omnicare and found CVS jointly and severally liable for $165 million of that amount.
A two-company future
The insurer and benefits businesses, plus Oak Street Health and Signify Health, would stay in a company temporarily called CVS Health. The other, CVS Pharmacy, would take retail and mail pharmacy, MinuteClinic and the Health100 technology business.
The split is intended to be tax-free to CVS and its shareholders. The company expects to finish it in the first half of 2028, subject to final board approval and a Form 10 registration statement becoming effective.
Quarter and opioid exposure
Third-quarter revenue rose 5.4% to $108.4 billion, and the company reported operating income of $3.6 billion against a $3.2 billion operating loss a year earlier, when a $5.7 billion goodwill impairment hit. In its earnings release, CVS raised full-year adjusted earnings guidance to at least $8.20 a share.
In October 2026 the company settled Justice Department opioid-dispensing claims for $315 million, previously accrued. Its remaining opioid accrual was about $3.4 billion at September 30.
The Omnicare asset sale is expected to close in the fourth quarter of 2026, which would trigger the agreements and CVS's $130 million payment.
Sources
- 10-Q Filing — CVS Health (CVS) — SEC EDGAR
- 10-Q Filing — CVS Health (CVS), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, cvs_ex99x1q3-26.htm) — CVS Health, filed 2026-11-04 — SEC EDGAR